Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 9/20 | 0.65 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.65 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.50 |
| ▸ | GGH | Q92820 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19225283 | 0.86 | FOLH1 (0.47) | FOLH1NAALAD2GRM3GGH | |
| SCHEMBL19220645 | 0.86 | FOLH1 (0.46) | FOLH1NAALAD2GRM3 | |
| SCHEMBL17504780 | 0.86 | FOLH1 (0.46) | FOLH1NAALAD2GRM3 | |
| SCHEMBL5134136 | 0.85 | GRM3 (0.74) | FOLH1NAALAD2GRM3 | |
| SCHEMBL16528808 | 0.79 | FOLH1 (1.00) | FOLH1NAALAD2GRM3 | |
| SCHEMBL383173 | 0.79 | FOLH1 (1.00) | FOLH1NAALAD2GRM3 | |
| SCHEMBL16528703 | 0.79 | FOLH1 (1.00) | FOLH1NAALAD2GRM3 | |
| SCHEMBL19225240 | 0.78 | FOLH1 (0.54) | FOLH1NAALAD2GRM3 | |
| SCHEMBL5134133 | 0.78 | GRM3 (0.68) | FOLH1NAALAD2GRM3 | |
| SCHEMBL19242717 | 0.78 | FOLH1 (0.54) | FOLH1NAALAD2GRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11325931-B2 | Prodrugs of prostate specific membrane antigen (PSMA) inhibitor | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-05-10 | — | — | US | disclosed |
| US-20200399298-A1 | PRODRUGS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR | THE JOHNS HOPKINS UNIVERSITY | 2020-12-24 | — | — | US | disclosed |
| US-20200069706-A1 | PRODRUGS OF 2-PMPA FOR HEALTHY TISSUE PROTECTION DURING PSMA-TARGETED CANCER IMAGING OR RADIOTHERAPY | BAYER HEALTHCARE HOLDINGS LLC | 2020-03-05 | — | — | US | disclosed |
| US-10544176-B2 | Prodrugs of prostate specific membrane antigen (PSMA) inhibitor | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-01-28 | — | — | US | disclosed |
| US-9988407-B2 | Prodrugs of prostate specific membrane antigen (PSMA) inhibitor | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-06-05 | — | — | US | disclosed |
| US-9988407-B2 | Prodrugs of prostate specific membrane antigen (PSMA) inhibitor | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-06-05 | — | — | US | disclosed |
| US-20170226141-A1 | PRODRUGS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-08-10 | — | — | US | disclosed |
| US-20170226141-A1 | PRODRUGS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-08-10 | — | — | US | disclosed |
| WO-2016022827-A1 | PRODRUGS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11325931-B2 | Prodrugs of prostate specific membrane antigen (PSMA) inhibitor | FOLH1, KLK3, DNPEP | FOLH1 1/4885NAALAD2 111/4885GRM3 1812/4885 |
| US-20170226141-A1 | PRODRUGS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR | FOLH1, KLK3, DNPEP | FOLH1 1/4885NAALAD2 111/4885GRM3 1812/4885 |
| US-20200399298-A1 | PRODRUGS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR | FOLH1, KLK3, DNPEP | FOLH1 1/4885NAALAD2 89/4885GRM3 1678/4885 |
| US-20200069706-A1 | PRODRUGS OF 2-PMPA FOR HEALTHY TISSUE PROTECTION DURING PSMA-TARGETED CANCER IMAGING OR RADIOTHERAPY | PLPBP, PTMA, PTPA | FOLH1 19/4885NAALAD2 406/4885GRM3 3112/4885 |
| US-10544176-B2 | Prodrugs of prostate specific membrane antigen (PSMA) inhibitor | FOLH1, KLK3, DNPEP | FOLH1 1/4885NAALAD2 111/4885GRM3 1812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.